| Name | Title | Contact Details |
|---|
JenaValve Technology, Inc., based in Irvine, California and Munich, Germany develops, manufactures and markets transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease. The Company’s transapical TAVI system is CE marked and currently marketed in Europe and other markets worldwide and its new transfemoral TAVI system is currently undergoing clinical evaluation in Europe with a view toward achieving CE Mark in 2015. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
DEXIS is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MicroOptx is an early stage medical device company that is building a platform technology to shunt aqueous humor from the anterior chamber to the surface of the eye. Our mission is to change the way the World treats glaucoma – halting the devastating effects of this progressive disease. MicroOptx is led by recognized medical, industry and financial veterans who are dedicated towards preventing blindness.
Equipoise Dental Laboratory is a Bergenfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. As The Imaging Phenomics Company®, Median provides insights into novel therapies and treatment strategies. Our unique solutions, MediScan® for lesion management in patient care, Lesion Management Solution (LMS) for lesion detection, measurement and reporting in clinical trials, and our imaging phenotyping system iBiopsy®, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world in bringing new and targeted treatments to patients in need with an eye on reducing overall costs. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris` Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass French Tech Promotion 2016-2017.